Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication November 22, 2022
- Revision received February 10, 2023
- Published online June 30, 2023.
Article Versions
- previous version (March 30, 2023 - 11:02).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Masatoshi Hotta*,1,
- Andrei Gafita*,1,
- Vishnu Murthy1,
- Matthias R. Benz1,
- Ida Sonni1,
- Irene A. Burger2,
- Matthias Eiber3,
- Louise Emmett4,
- Andrea Farolfi1,5,
- Wolfgang P. Fendler6,
- Manuel M. Weber6,
- Michael S. Hofman7,
- Thomas A. Hope8,
- Clemens Kratochwil9,
- Johannes Czernin1 and
- Jeremie Calais1
- 1Ahmanson Translational Theranostics Division, UCLA, Los Angeles, California;
- 2Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland;
- 3Department of Nuclear Medicine, Technical University Munich, Munich, Germany;
- 4Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
- 5Nuclear Medicine, IRCCS Azienda Ospedaliero–Universitaria di Bologna, Bologna, Italy;
- 6Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital Essen, Essen, Germany;
- 7Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
- 8Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; and
- 9Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
- For correspondence or reprints, contact Masatoshi Hotta (mhotta.11.11{at}gmail.com).
↵* Contributed equally to this work.
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- 99mTc-MIP-1404 SPECT/CT Companion Diagnostic for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
- The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy
- Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes
- Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers